The spectrum of therapeutic activity of mepolizumab

References

• Lu YF, Goldstein DB, Angrist M, et al. Personalized medicine and human genetic diversity. Cold Spring Harb Perspect Med. 2014;4(9):a008581.
   PubMed Web of Science ®Google Scholar
• Yii ACA, Tay TR, Choo XN, et al. Precision medicine in united airways disease: a “treatable traits” approach. Allergy. 2018;73(10):1964–1978.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Mauro M, Makri E, et al. Two decades with omalizumab, what we still have to learn. Biologics. 2018;12:135–142.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111(4):714–719.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Mepolizumab and eosinophil-mediated disease. Curr Med Chem. 2009;16(36):4774–4778.
   PubMed Web of Science ®Google Scholar
• Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011;7(4):411–417.
   PubMed Web of Science ®Google Scholar
• Heinecke JW. Eosinophil-dependent bromination in the pathogenesis of asthma. J Clin Invest. 2000;105(10):1331–1332.
   PubMed Web of Science ®Google Scholar
• Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy. 2003;33(12):1622–1628.
   PubMed Web of Science ®Google Scholar
• Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010;11(7):577–584.
   PubMed Web of Science ®Google Scholar
• Eng SS, De Felice ML. The role and immunobiology of eosinophils in the respiratory system: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(2):140–158.
   PubMed Web of Science ®Google Scholar
• Dunlap NE, Fulmer JD. Corticosteroid therapy in asthma. Clin Chest Med. 1984;5(4):669–6683.
   PubMed Web of Science ®Google Scholar
• Chung KF. Managing severe asthma in adults: lessons from the ERS/ATS guidelines. Curr Opin Pulm Med. 2015;21(1):8–15.
   PubMed Web of Science ®Google Scholar
• Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and late asthmatic response. Lancet. 2000;356(9248):2144–2148.
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophils role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(12):199–204.
   PubMedGoogle Scholar
• Flood-Page PT, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling C, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini M, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howart P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Ortega H, Li H, Suruki R, et al. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc. 2014;11(7):1011–1017.
   PubMedGoogle Scholar
• Varricchi G, Bagnasco D, Ferrando M, et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence an practical exprerience. Ther Adv Respir Dis. 2017;11:40–45.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al.; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al.; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;7:CD010834.
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018 Nov 29;52(5). pii: 1801393. doi: 10.1183/13993003.01393-2018.
   PubMed Web of Science ®Google Scholar
• Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097.
   PubMed Web of Science ®Google Scholar
• Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med. 2017;196(11):1385–1395.
   PubMed Web of Science ®Google Scholar
• Shrimanker R, Pavord ID, Yancey S, et al. Exacerbations of severe asthma in patients treated with mepolizumab. Eur Respir J. 2018 Dec 13;52(6). pii: 1801127. doi: 10.1183/13993003.01127-2018.
   Web of Science ®Google Scholar
• Basu A, Dalal A, Canonica GW, et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):121–131.
   PubMed Web of Science ®Google Scholar
• Bermejo I, Stevenson M, Cooper K, et al. Mepolizumab for treating severe eosinophilic asthma: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(2):131–144.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7. doi: 10.1016/j.jaci.2018.09.033.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Solinas S, et al. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. Pulm Pharmacol Ther. 2018;53:1–5.
   PubMed Web of Science ®Google Scholar
• Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152–160.
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Scioscia G, Lacedonia D, et al. Severe uncontrolled asthma with bronchiectasis; a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy. 2019;12:83–90.
   PubMed Web of Science ®Google Scholar
• Farah CS, Badal T, Reed N, et al. Mepolizumab improves small airway function in severe eosinophilic asthma. Respir Med. 2019;148:49–53.
   PubMed Web of Science ®Google Scholar
• Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Mullol J, et al.. EPOS 2012: European position paper on rhinosinusitis and nasal polyps. A summary for otorhinolaryngologists. Rhinology 2012;50(1):1–12.
   PubMed Web of Science ®Google Scholar
• Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54(26):1–30.
   PubMedGoogle Scholar
• Brescia G, Zanotti C, Parrino D. Nasal polyposis pathophysiology: endotype and phenotype open issues. Am J Otolaryngol. 2018;39(4):441–444.
   PubMed Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024–1031.
   PubMed Web of Science ®Google Scholar
• Rivero A, Liang J. Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis. Ann Otol Rhinol Laryngol. 2017;126(11):739–747.
   PubMed Web of Science ®Google Scholar
• Cavaliere C, Incorvaia C, Frati F, et al. Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps. Clin Mol Allergy. 2019;17:3.
   PubMedGoogle Scholar
• Dellon ES. Eosinophilic esophagitis. Gastroenterol Clin North Am. 2013;42(1):133–153.
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30.
   PubMed Web of Science ®Google Scholar
• Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593–1604.
   PubMed Web of Science ®Google Scholar
• Tomizawa Y, Melek J, Komaki Y, et al. Efficacy of pharmacologic therapy for eosinophilic esophagitis: a systematic review and network meta-analysis. J Clin Gastroenterol. 2018;52(7):596–606.
   PubMed Web of Science ®Google Scholar
• Noh HR, Magpantay GG. Hypereosinophilic syndrome. Allergy Asthma Proc. 2017;38(1):78–81.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, et al.; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 200820;358(12):1215–1228.
   PubMed Web of Science ®Google Scholar
• Roufosse F, de Lavareille A, Schandené L, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126(4):828–835.
   PubMed Web of Science ®Google Scholar
• Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131(2):461–467.
   PubMed Web of Science ®Google Scholar
• Wu EY, Hernandez ML, Jennette JC, et al. Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review. J Allergy Clin Immunol Pract. 2018;6(5):1496–1504.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al.; EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 201718;376(20):1921–1932.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sehgal IS, Dhooria S, et al. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med. 2016;10(12):1317–1334.
   PubMed Web of Science ®Google Scholar
• Hirota S, Kobayashi Y, Ishiguro T, et al. Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: case report and review of the literature. Respir Med Case Rep. 2018;26:59–62.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Kjarsgaard M, Capaldi D, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017 Mar 15;49(3). pii: 1602486. doi: 10.1183/13993003.02486-2016.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629.
   PubMed Web of Science ®Google Scholar
• Fernandez Romero GA, Beros J, Criner G. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations. Expert Rev Respir Med. 2019;13(2):125–132.
   PubMed Web of Science ®Google Scholar
• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158–166.
   PubMedGoogle Scholar
• Caruso M, Morjaria J, Emma R, et al. Biologic agents for severe asthma patients: clinical perspectives and implications. Intern Emerg Med. 2018;13(2):155–176.
   PubMed Web of Science ®Google Scholar
• Skolnik NS, Carnahan SP. Primary care of asthma: new options for severe eosinophilic asthma. Curr Med Res Opin. 2019;35:1309–1318. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Jeimy S, Tsoulis MW, Hachey J, et al. Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective. Allergy Asthma Clin Immunol. 2018;14:68.
   PubMed Web of Science ®Google Scholar